Search Results
Your search for ,Med matches 2731 pages
Showing 351 - 400IMbrave050 Trial: Adjuvant Regimen of Atezolizumab Plus Bevacizumab in Resectable Hepatocellular Carcinoma
Adjuvant treatment with the combination of atezolizumab and bevacizumab achieved a statistically significant and clinically meaningful improvement in recurrence-free survival compared with active surveillance alone in patients with high-risk hepatocellular carcinoma following curative-intent...
NOVA: Final Analysis Confirms No Significant Overall Survival Benefit for Maintenance Niraparib in Recurrent Ovarian Cancer
After resolving missing survival data in the phase III ENGOT-OV16/NOVA trial, no statistically significant difference in overall survival was found for patients with platinum-sensitive recurrent ovarian cancer who received maintenance therapy with the PARP inhibitor niraparib, investigators...
Expert Point of View: Amanda Nickles Fader, MD
Amanda Nickles Fader, MD, Professor of Gynecology and Obstetrics, Professor of Oncology, and Vice Chair of Gynecologic Surgical Operations at Johns Hopkins Health System, Baltimore, provided her thoughts on GOG 3026 for The ASCO Post. Dr. Fader applauded the investigators and the Gynecologic...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Personalized Mind-Body Medicine in Integrative Oncology
Guest Editor’s Note: Substantial evidence supports the value of practices that focus on the interactions among the mind, body, and behavior for promoting health and well-being. In this article, Kavita K. Mishra, MD, MPH, summarizes a clinical model for personalized mind-body medicine in cancer care ...
Cancer Immunology and Immunotherapy: Principles and Practice
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, we begin a new series of articles on cancer immunology and immunotherapy, in which the authors discuss how immunotherapy has become a major pillar of...
ASCO Releases Guideline Updates for Stage IV NSCLC With and Without Driver Alterations
ASCO has updated two living guidelines on the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations with the inclusion of new evidence-based treatment recommendations.1,2 Among the updates, the guidelines add the recently approved RAS GTPase family...
Lung Cancer Screening and Possible Unappreciated Benefits
Screening that reduces cancer mortality serves as a foundational element of impactful care for certain cancers. That said, harms related to screening deserve our attention—overdiagnoses; diagnostic odysseys that may be invasive, expensive, or even unintentionally harmful; overtreatment of diagnosed ...
Immunotherapy/Chemotherapy Combination Prolongs Survival in Advanced Biliary Tract Cancers
The addition of the checkpoint inhibitor pembrolizumab to chemotherapy with cisplatin/gemcitabine as first-line therapy improved overall survival in patients with advanced biliary tract cancer, according to results of the KEYNOTE-966 trial presented at the 2023 American Association for Cancer...
Elena Garralda, MD, MSc, Discusses Findings From the KRYSTAL-1 Trial
Elena Garralda, MD, MSc, Director of Early Drug Development at Vall d’Hebron University Hospital and Director of the Phase I Unit at NEXT Oncology, Barcelona, was invited to discuss the KRYSTAL-1 findings. “In KRYSTAL-1, adagrasib monotherapy has demonstrated clinically meaningful activity in a...
Exercise and Wellness Programs May Enhance Well-Being and Reduce Health-Care Costs in Patients With Breast Cancer
Two new studies revealed that specialized exercise and wellness programs may significantly increase physical well-being and quality of life as well as reduce health-care costs in patients with breast cancer, according to findings presented by Wonders et al and Brahmbhatt et al at the 24th American...
GOG 258 Final Results: No Improvement in Survival by Adding Radiotherapy to Chemotherapy in Advanced Endometrial Cancer
The long-running randomized NRG Oncology GOG-258 clinical trial failed to identify an overall survival benefit with adjuvant chemoradiotherapy vs chemotherapy alone in any subgroup of patients with locally advanced endometrial cancer. After a median follow-up of 112 months, the hazard ratio for...
Emerging Success With Novel Targeted Therapies in Endocrine-Resistant Metastatic Breast Cancer
In hormone receptor–positive breast cancer, the ability to successfully target key mediators of endocrine resistance is changing the outlook of metastatic disease in this subtype, according to Aditya Bardia, MD, MPH, FASCO, Director of Breast Cancer Research and Associate Professor at Harvard...
Checkpoint Inhibitors Poised to Change Standard of Care in Advanced Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced endometrial cancer reduced the risk of disease progression or death by 70% in patients with mismatch repair–deficient (dMMR) tumors in two recent phase III studies. The results of the two...
Addressing Racial Disparities in Cancer Pain Management: A Potential Role for Music Therapy
Guest Editor’s Note: Despite its high prevalence, cancer pain remains undertreated. Racial disparities present further challenges to assessing and managing pain. Music therapy, a nonpharmacologic intervention, has been documented to be effective in controlling cancer pain. In this article, Kevin T. ...
Yes, You Should Attend the 2023 ASCO Annual Meeting
The questions I am challenged to answer are twofold: (1) Should you attend the 2023 ASCO Annual Meeting? (2) If you attend, how is your time best spent? Most people agree scientific conferences are important venues for cancer researchers and clinicians to share and discuss research findings,...
Which Patients With Breast Cancer Can Omit Radiotherapy?
Although advances in radiation therapy have rendered this treatment modality more tolerable, they have not completely eliminated the burden of radiation-related toxicity. In an ideal setting, clinicians would be able to identify patients whose risk of recurrence is sufficiently low that they can...
Early-Stage Triple-Negative Breast Cancer: Optimizing Therapy
The management of early-stage triple-negative breast cancer has been evolving at a fast pace, thanks largely to the discovery that immune checkpoint blockade can be effective in this subtype. At the 2023 Miami Breast Cancer Conference, Priyanka Sharma, MD, Professor of Medicine, University of...
Neoadjuvant Pembrolizumab in Desmoplastic Melanoma
Neoadjuvant pembrolizumab may significantly improve the management of desmoplastic melanoma, increasing the likelihood of successful resection and reducing the need for further surgery or radiation therapy, according to the response data presented at the 2022 ASCO Annual Meeting, with the surgical...
How Effectively Are You Helping Patients With Cancer at the End of Life?
“Providing hope when there is little to hope for is hard,” noted Hyman B. Muss, MD, Professor of Medicine and the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center. At the 2023 Miami...
It Is Time to Close the Gap in Cancer Care
Cancer is a leading cause of death in every country worldwide.1 In 2020, almost 10 million people died of cancer, a number that is expected to rise to 16.3 million by 2040.2 In addition, cancer incidence continues to grow, driven by an aging and growing population and changes in the prevalence and...
ASCO Updates Guideline on Sacituzumab Govitecan-hziy in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
ASCO has released a rapid recommendation update to the guideline on chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor–negative metastatic breast cancer, addressing the use of sacituzumab govitecan-hziy in patients with endocrine-resistant, hormone receptor–positive,...
DESTINY-Breast03: T-DXd Improves Overall Survival vs T-DM1 in Previously Treated HER2-Positive Metastatic Breast Cancer
As reported in The Lancet by Sara A. Hurvitz, MD, of the David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, and colleagues, updated results of the phase III DESTINY-Breast03 trial showed significantly improved overall survival with...
Sotorasib Improves Progression-Free Survival vs Docetaxel in Previously Treated Advanced NSCLC With KRAS G12C Mutation
As reported in The Lancet by Adrianus Johannes de Langen, MD, PhD, of the Netherlands Cancer Institute, Amsterdam, and colleagues, the phase III CodeBreaK200 trial has shown a small but significant improvement in progression-free survival with sotorasib vs docetaxel in previously treated advanced...
Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Paula Rodriguez-Otero, MD, PhD, of Clínica Universidad de Navarra, Pamplona, Spain, and colleagues, an interim analysis of the phase III KarMMa-3 trial has shown superior progression-free survival with the B-cell maturation antigen–directed...
Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...
Use of Low-Dose Naltrexone
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus...
Zanubrutinib Improves Progression-Free Survival vs Ibrutinib in Relapsed or Refractory CLL or SLL
As reported in The New England Journal of Medicine by Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute and Harvard University, and colleagues, the phase III ALPINE trial has shown significantly better progression-free survival with zanubrutinib, a Bruton’s tyrosine kinase (BTK)...
Walks on a Beach With an Inspiring Grandfather Led to a Career in Cancer Research and Drug Development for Vivek Subbiah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Vivek Subbiah, MD, Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine Division, at The University of Texas MD Anderson Cancer Center, ...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Nuances in Breast Cancer Imaging for Screening and Surveillance
Breast cancer screening and imaging-based surveillance after treatment remain suboptimal, largely because of confusion in the guidelines and the fact that dense breasts are too often ignored, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology...
Understanding Fertility Issues in Young Patients With Breast Cancer
Young women with breast cancer have many concerns about their future fertility. How confident are you in discussing their chances of a future pregnancy, the effect of breast cancer treatment and fertility interventions on these offspring, and their risk of a compromised oncologic outcome after...
Elizabeth Smyth, MD, Offers Insight on KEYNOTE-859 Findings
The invited discussant of KEYNOTE-859,1 Elizabeth Smyth, MD, consultant in gastrointestinal oncology at Cambridge University Hospitals NHS Foundation Trust in the United Kingdom, called the findings “practice-changing” but cautioned that better patient selection is needed to optimally apply them....
Novel Herbal Oncology Program for Management of Cancer Symptoms at an NCI-Designated Cancer Center
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, Guest Editor of the Integrative Oncology series, and Yen ...
Expert Point of View: Anjali S. Advani, MD
Discussant of the February ASCO Plenary session, Anjali S. Advani, MD, Staff Physician in the Department of Hematologic Oncology and Blood Disorders and Director of the Inpatient Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, noted that the PhALLCON study is the only prospective...
Working Together to Close the Global Care Gap
The COVID-19 pandemic has underscored that public health is the product of one global, integrated ecosystem. Although it is tempting to focus on specific aspects of local health-care systems, or the political or physical environment, health and health care in other countries also impacts the United ...
TRITON3 Trial: Rucaparib Extends Progression-Free Survival in Selected Patients With Metastatic Castration-Resistant Prostate Cancer
The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib prolonged imaging-based progression-free survival vs physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer whose tumors harbored BRCA or ATM alterations. These results of the phase III TRITON3 study ...
ASCO Updates ‘Living’ Guidelines on Stage IV NSCLC Based on DESTINY-Lung01, CodeBreaK100, Other Trials
ASCO has updated its living guidelines for therapy for stage IV non–small cell lung cancer (NSCLC) with and without driver alterations based on newly available evidence in the field.1,2 “Living guidelines are becoming more important as the field of oncology expands and developments occur more...
Expert Point of View: Adam M. Brufsky, MD
Commenting on the study from Tata Memorial Centre for The ASCO Post, Adam M. Brufsky, MD, Professor of Medicine, Associate Chief of the Division of Hematology/Oncology and Co-Director of the Comprehensive Breast Cancer Center at the University of Pittsburgh School of Medicine, noted that the...
Expert Point of View: Pretesh R. Patel, MD
Session co-moderator, Pretesh R. Patel, MD, Associate Professor of Radiation Oncology at Winship Cancer Institute of Emory University, shared his thoughts on the Neo-AEGIS1 findings with The ASCO Post. “I think we continue to have equipoise about chemoradiation and perioperative chemotherapy in...
Neo-AEGIS Trial Finds Two Approaches Comparable in Treating Advanced Esophageal Cancer
A randomized trial that sought to determine the optimal approach to treating locally advanced esophageal or gastroesophageal junction cancer has ended in “equipoise,” according to the investigators of the Neo-AEGIS trial. In a study reported at the 2023 ASCO GI Cancers Symposium, perioperative...
Expert Point of View: Laura Goff, MD, MSCI
Invited discussant Laura Goff, MD, MSCI, Associate Professor of Medicine and Executive Medical Director for the Cancer Patient Care Center at Vanderbilt-Ingram Cancer Center, Nashville, said that with the results of NAPOLI-3, clinicians have a third effective first-line regimen for metastatic...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
Addition of Bevacizumab to Trifluridine/Tipiracil: New Standard of Care in Refractory Colorectal Cancer
In the open-label phase III SUNLIGHT trial, the addition of bevacizumab to trifluridine/tipiracil, also known as TAS-102, significantly improved overall survival in patients with metastatic treatment-refractory colorectal cancer,1 according to Josep Tabernero, MD, Head of the Department of Medical...
Neighborhood Social Vulnerability and Its Influence on the Availability of Clinical Trials in Multiple Myeloma
Clinical trials set the treatment standards for cancer care. However, for select populations, such as those who are older, Black, or facing socioeconomic challenges, access to clinical trials and health care generally remains limited. Barriers to clinical trial participation are numerous and...
Triplet and Quadruplet Regimens in Smoldering Multiple Myeloma
Combination regimens beyond lenalidomide/dexamethasone were shown to significantly delay—and potentially prevent altogether—progression from smoldering disease to active multiple myeloma, according to researchers who reported findings from two studies at the 2022 American Society of Hematology...
Abstracts of Interest on Novel Therapies for Gastrointestinal Cancers
As in the years before the COVID-19 pandemic, the 2023 ASCO GI Cancers Symposium—its 20th such gathering—played to a full ballroom. It featured a stellar lineup of experts in the field as well as high-quality, impactful research in esophageal, gastric, hepatocellular, pancreatic, biliary tract, and ...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
